Pfizer Inc. (PFE) Stock Analysis
$PFE · Healthcare · Drug Manufacturers - General · NYSE
Pfizer (PFE), a Drug Manufacturers - General company, is listed on NYSE, has a market capitalization of about $167.51B and trades at 41.6x trailing earnings.
Price
$29.39
Market cap
$167.51B
P/E ratio
41.6x
Dividend yield
5.85%
About Pfizer Inc.
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar fa
How StockWorthy values PFE
StockWorthy forecasts Pfizer Inc.'s revenue, operating profitability, reinvestment (capital expenditure, depreciation and working capital) and unlevered free cash flow, then discounts those cash flows using a normalized cost of capital built from PFE's size, profitability and balance-sheet risk. Terminal growth is adjusted to reflect the company's mature growth profile rather than a fixed number. The model presents bear, base and bull scenarios, and every key assumption stays transparent and adjustable in the full StockWorthy analysis. Results are educational and not investment advice.
Related stocks
See PFE's Fair Value
Create a free account to view Pfizer Inc.'s base-case fair value, the bear–bull modeled range, and every assumption behind them. Free accounts include 5 stock valuations per month — plus Advanced DCF models, financial charts, dividends, and peer analysis.